An insight into JAK-STAT signalling in dermatology

Clinical and Experimental Dermatology

Volumn 39, Issue 4, 2014, Pages 513-518

  Palanivel, J A ^a   Macbeth, A E ^b,c   Chetty, N C ^b   Levell, N J ^b  

^a Derme Cure Skin Clinic   (India)

^b NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^c CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CUCURBITACIN; DERMATOLOGICAL AGENT; JANUS KINASE; JANUS KINASE INHIBITOR; PROTEIN INHIBITOR; RUXOLITINIB; STAT INHIBITOR; STAT PROTEIN; TOFACITINIB; UNCLASSIFIED DRUG; PROTEIN INHIBITOR OF ACTIVATED STAT; PROTEIN KINASE INHIBITOR;

ALOPECIA AREATA; CELL DEATH; CELL PROLIFERATION; CONFORMATIONAL TRANSITION; DERMATOLOGY; GENE CONTROL; GENE MUTATION; HEMATOPOIESIS; HUMAN; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PSORIASIS; PYODERMA GANGRENOSUM; REVIEW; SIGNAL TRANSDUCTION; SKIN DISEASE; T LYMPHOCYTE; TUMOR CELL; ARTICLE; ATOPIC DERMATITIS; ENZYME ACTIVATION; ENZYME INHIBITION; ANTAGONISTS AND INHIBITORS; PATHOPHYSIOLOGY; PHYSIOLOGY; SKIN DISEASES;

HUMANS; JANUS KINASES; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; SKIN DISEASES; STAT TRANSCRIPTION FACTORS;

EID: 84900398998     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/ced.12273     Document Type: Review

References (30)

1. Rawlings JS, Rosler KM, Harrison AD,. The JAK/STAT signalling pathway. J Cell Sci 2004; 117: 1281-3.
2. Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW,. Signalling through the JAK/STAT pathway, recent advances and future challenges. Gene 2002; 285: 1-24.
3. Levine RL, Wadleigh M, Cools J, et al,. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-97.
4. Walker JG, Ahern MJ, Coleman M, et al,. Characterisation of a dendritic cell subset in synovial tissue which strongly expresses Jak/STAT transcription factors from patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66: 992-9.
5. Chen C, Zhang X, Wang Y,. Analysis of JAK2 and STAT3 polymorphisms in patients with ankylosing spondylitis in Chinese Han population. Clin Immunol 2010; 136: 442-6.
6. Ferguson LR, Han DY, Fraser AG, et al,. Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn's disease in a New Zealand population. Mutat Res 2010; 690: 108-15.
7. Anderson CA, Massey DCO, Barrett JC, et al,. Investigation of Crohn's disease risk loci in Ulcerative colitis further defines their molecular relationship. Gastroenterology 2009; 136: 523-9.
8. Bernabei P, Coccia EM, Rigamonti L, et al,. Interferon-gamma receptor 2 expression as the deciding factor in human T, B, and myeloid cell proliferation or death. J Leukoc Biol 2001; 70: 950-60.
9. Kumar A, Commane M, Flickinger TW, et al,. Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. Science 1991; 278: 1630-2.
10. Real PJ, Sierra A, De Juan A, et al,. Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 2002; 21: 7611-18.
11. Alas S, Bonavida B,. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug mediated apoptosis. Clin Cancer Res 2003; 9: 316-26.
12. Duan Z, Bradner J, Greenberg E, et al,. 8-benzyl-4-oxo-8-azabicyclo[3.2. 1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells. Mol Pharmacol 2007; 72: 1137-45.
13. Nishio H, Matsui K, Tsuji H, et al,. Immunolocalisation of the Janus kinases (JAK)-signal transducers and activators of transcription (STAT) pathway in human epidermis. J Anat 2001; 198: 581-9.
14. Matsumoto M, Ra C, Kawamoto K, et al,. IgE hyperproduction through enhanced tyrosine phosphorylation of Janus kinase 3 in Nc/Nga mice, a model for human atopic dermatitis. J Immunol 1999; 162: 1056-63.
15. Leonard W, O'Shea JJ,. Jaks and Stats: biological implications. Annu Rev Immunol 1998; 16: 293-322.
16. Chang BY, Zhao F, He X, et al,. JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice. J Immunol 2009; 183: 2183-92.
17. Sigurdsson S, Nordmark G, Goring HH, et al,. Polymorphisms in the Tyrosine kinase 2 and Interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet 2005; 76: 528-37.
18. Cunninghame Graham DS, Akil M, Vyse TJ,. Association of polymorphisms across the tyrosine kinase gene, TYK2 in UK SLE families. Rheumatology 2007; 46: 927-30.
19. Palanivel JA, Macbeth AE, Levell NJ,. Pyoderma gangrenosum in association with Janus kinase 2 (JAK2V617F) mutation. Clin Exp Dermatol 2013; 38: 44-6.
20. Mortarini R, Vegetti C, Molla A, et al,. Impaired stat phosphorylation in cells from melanoma patients in response to IL-2: association with clinical stage. Clin Cancer Res 2009; 15: 4085-94.
21. Brender C, Nielsen M, Kaltoft K, et al,. STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma. Blood 2001; 97: 1056-62.
22. Moran N,. Incyte comes of age with JAK inhibitor approval. Nat Biotechnol 2012; 30: 3-5.
23. Tanaka Y, Suzuki M, Nakamura H, et al,. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res 2011; 63: 1150-8.
24. Burmester GR, Blanco R, Charles-Schoeman C, et al,. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomd phase 3 trial. Lancet 2013; 381: 451-60.
25. Boy MG, Wang C, Wilkinson BE, et al,. Double-blind, placebo-controlled, does-escalation study to evaluate the pharmacologic effect of CP-69,550 in patients with psoriasis. J Invest Dermatol 2009; 129: 2299-302.
26. Papp KA, Menter A, Strober B, et al,. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol 2012; 167: 668-77.
27. Ports WC, Khan S, Lan S, et al,. A randomised Phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol 2013; 169: 137-45.
28. Jabbari A, Dai Z, Xing L, et al,. Reversal of long-standing alopecia areata in C3H/HeJ mice using topical JAK inhibitors. J Invest Dermatol 2013; 133 (Suppl 1): S38 (abstract).
29. Blaskovich MA, Sun J, et al,. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 2003; 63: 1270-9.
30. Van Kester SM, Out-Luiting JJ, et al,. Cucurbitacin I inhibits Stat3 and induces apoptosis in Sezary cells. J Invest Dermatol 2008; 128: 1691-5.